Hepatocellular carcinoma: Sorafenib before liver transplantation?
Alain Braillon – 23 May 2010
Right atrial pressure is not adequate to calculate portal pressure gradient in cirrhosis: A clinical‐hemodynamic correlation study
Vincenzo La Mura, Juan G. Abraldes, Annalisa Berzigotti, Eva Erice, Alexandra Flores‐Arroyo, Juan Carlos García‐Pagán, Jaime Bosch – 23 May 2010 – Hepatic venous pressure gradient (HVPG), the difference between wedge and free hepatic venous pressure, is the preferred method for estimating portal pressure. However, it has been suggested that hepatic atrial pressure gradient (HAPG)—the gradient between wedge hepatic venous pressure and right atrial pressure (RAP)—might better reflect variceal hemodynamics.
Inhibitory role of peroxisome proliferator‐activated receptor gamma in hepatocarcinogenesis in mice and in vitro
Jun Yu, Bo Shen, Eagle S. H. Chu, Narci Teoh, Kin‐Fai Cheung, Chung‐Wah Wu, Shiyan Wang, Cleo N. Y. Lam, Hai Feng, Junhong Zhao, Alfred S. L. Cheng, Ka‐Fai To, Henry L. Y. Chan, Joseph J. Y. Sung – 23 May 2010 – Although peroxisome proliferator‐activated receptor gamma (PPARγ) agonist have been shown to inhibit hepatocellular carcinoma (HCC) development, the role of PPARγ in hepatocarcinogenesis remains unclear. We investigated the therapeutic efficacy of PPARγ against HCC.
Low levels of 25‐hydroxyvitamin D3 in children with biopsy‐proven nonalcoholic fatty liver disease
Melania Manco, Paolo Ciampalini, Valerio Nobili – 23 May 2010
A young woman with a large mass in the right hepatic lobe
Florian Grabellus, Knut M. Nowak – 23 May 2010
Identifying hepatitis C virus genotype 2/3 patients who can receive a 16‐week abbreviated course of peginterferon alfa‐2a (40KD) plus ribavirin
Moises Diago, Mitchell L. Shiffman, Jean‐Pierre Bronowicki, Stefan Zeuzem, Maribel Rodriguez‐Torres, Stephen C. Pappas, Andreas Tietz, David R. Nelson – 23 May 2010 – The objective of this analysis was to compare sustained virological response (SVR) and relapse rates in patients with a rapid virological response (RVR, HCV RNA <50 IU/mL at week 4) randomized to 24 or 16 weeks of treatment with peginterferon alfa‐2a (40KD) 180 μg/week plus ribavirin 800 mg/day in the multinational ACCELERATE study.
Personalized medicine in hepatitis C: From genome‐wide association studies to clinical practice
Hermann E. Wasmuth, Ralf Weiskirchen – 23 May 2010
“Neonatal hemochromatosis”: A re‐vision
A. S. Knisely, Diego Vergani – 23 May 2010
Themes of liver transplantation
Thomas E. Starzl, John J. Fung – 23 May 2010 – Liver transplantation was the product of five interlocking themes. These began in 1958‐1959 with canine studies of then theoretical hepatotrophic molecules in portal venous blood (Theme I) and with the contemporaneous parallel development of liver and multivisceral transplant models (Theme II). Further Theme I investigations showed that insulin was the principal, although not the only, portal hepatotrophic factor.
Drug‐induced autoimmune hepatitis: Clinical characteristics and prognosis
Einar Björnsson, Jayant Talwalkar, Sombat Treeprasertsuk, Patrick S. Kamath, Naoki Takahashi, Schuyler Sanderson, Matthias Neuhauser, Keith Lindor – 23 May 2010 – Drug‐induced autoimmune hepatitis (DIAIH) has been reported to be caused by several drugs. There is a lack of data comparing these patients with other patients with autoimmune hepatitis (AIH). A search was performed using the Mayo Clinic diagnostic medical index for AIH patients and DIAIH patients identified over 10 years. Individuals with overlap syndromes and decompensated liver disease were excluded.